The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.00
Bid: 27.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 2.00 (7.407%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 28.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Renewal of Contracts

4 Mar 2011 08:00

RNS Number : 3373C
Ilika plc
04 March 2011
 



 

 

4 March 2011

Ilika plc

 

("Ilika" or the "Company")

 Renewal of Contracts

Ilika plc (AIM: IKA), the advanced cleantech materials discovery company, is pleased to announce it has renewed and extended the scope of contracts with a major existing customer for the development of novel battery materials. Together with other secured orders, these contracts bring the level of committed revenues to more than £1.8 million for the current financial year ending 30 April 2011. Committed revenues for the financial year ending 30 April 2012 are now in excess of £0.5 million in aggregate.

Commenting on the contracts, Graeme Purdy, CEO of Ilika, said: "These renewals confirm customer appreciation of the value Ilika brings to product development programmes. We are delighted to extend our relationship with this particular customer into the next project phase. This collaboration reinforces Ilika's position as a globally-leading provider of materials expertise for the rapid development of next generation battery materials. In particular, Ilika's ability to rapidly synthesize candidate materials and test them using proprietary high-throughput electrochemical screening methods continues to be seen as a unique differentiator by our partners and customers."

 

- Ends -

 For more information contact:

 

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

+44 (0) 23 80111400

 

Nomura Code Securities Limited

Phil Walker / Christopher Golden

+44 (0) 20 7776 1200

Pelham Bell Pottinger

Archie Berens / Olly Scott / Francesca Tuckett

+44 (0) 20 7861 3232

 

 

 

About Ilika 

Ilika is an advanced materials company which accelerates the discovery of new and patentable materials using its unique high throughput technologies (''HTT'') process for identified end uses in the energy, electronics and biomedical sectors. This process enables hundreds of scalable materials to be made in a single, automated operation and subsequently tested for key properties.

Traditionally, materials development has been a slow and arduous task, with manual, sequential methods used to make samples of material that are then tested for suitability. On average, it takes between 7 and 10 years to move from an initial discovery through to the first commercial prototype. Experiments carried out by the Company can be executed 10 to 100 times faster than using traditional techniques.

The Company focuses on three principal sectors and has a number of active development programmes addressing markets within each sector:

Energy - developing innovative new materials for Lithium-ion batteries for vehicles for Toyota; developing high capacity hydrogen storage materials with Shell Hydrogen and Johnson Matthey through joint development programmes; developing cheaper alternatives to Platinum electrodes for use in fuel cells through a grant-funded project with the Carbon Trust; developing new materials for use in fuel cells for the transport sector for a major vehicle manufacturer; and carrying out in-house research on film photovoltaic solar cells.

Electronics - developing lead-free piezoelectric materials through a joint development programme with CeramTec; developing phase change memory materials for high capacity memory chips and high-performing electronic materials for a multi-national manufacturer.

Biomedical - developing polymers to enable the filtering of somatic stem cells from blood with a major global supplier of filters; it has been selling its Cryoskin and Myskin products for the treatment of burns and wounds in the UK through a specialist distributor and intends to commence clinical trials of its corneal bandage candidate.

The Group's commercialisation strategy is to enter into joint development or licensing agreements with large multinational companies which are seeking to commercialise products developed using the intellectual property created through jointly-funded programmes. Current commercialisation partners include large multinational companies such as Toyota, Shell, Johnson Matthey and CeramTec. The Company generates revenues from three sources: licensing and milestone payments from joint development programmes; fee for service from contract research projects; and from sales of Cryoskin and Myskin.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAXDLELNFEEF
Date   Source Headline
5th Jul 202111:05 amRNSSecond Price Monitoring Extn
5th Jul 202111:00 amRNSPrice Monitoring Extension
23rd Jun 202111:06 amRNSSecond Price Monitoring Extn
23rd Jun 202111:05 amRNSPrice Monitoring Extension
22nd Jun 20219:02 amRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSTrading Update & Notice of Results
8th Apr 20217:00 amRNSAppointment of Berenberg as Joint Corporate Broker
6th Apr 20217:00 amRNSGoliath manufacturing design collaboration
18th Mar 20217:00 amRNSISO Certification
4th Mar 20215:30 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSStereax Manufacturing Update
11th Feb 20214:30 pmRNSAward of Share Options
19th Jan 20214:42 pmRNSSecond Price Monitoring Extn
19th Jan 20214:36 pmRNSPrice Monitoring Extension
14th Jan 202111:07 amRNSSecond Price Monitoring Extn
14th Jan 202111:01 amRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSHalf-year Report
12th Jan 20214:37 pmRNSPrice Monitoring Extension
11th Jan 20214:41 pmRNSSecond Price Monitoring Extn
11th Jan 20214:37 pmRNSPrice Monitoring Extension
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:37 pmRNSPrice Monitoring Extension
6th Jan 20214:42 pmRNSSecond Price Monitoring Extn
6th Jan 20214:39 pmRNSPrice Monitoring Extension
6th Jan 20212:06 pmRNSSecond Price Monitoring Extn
6th Jan 20212:01 pmRNSPrice Monitoring Extension
6th Jan 202111:06 amRNSSecond Price Monitoring Extn
6th Jan 202111:01 amRNSPrice Monitoring Extension
6th Jan 20219:06 amRNSSecond Price Monitoring Extn
6th Jan 20219:00 amRNSPrice Monitoring Extension
29th Dec 20204:36 pmRNSPrice Monitoring Extension
29th Dec 202010:04 amRNSStmnt re Share Price Movement
24th Dec 20201:06 pmRNSHolding(s) in Company
23rd Dec 20204:41 pmRNSSecond Price Monitoring Extn
23rd Dec 20204:36 pmRNSPrice Monitoring Extension
23rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:01 pmRNSPrice Monitoring Extension
23rd Dec 202011:06 amRNSSecond Price Monitoring Extn
23rd Dec 202011:01 amRNSPrice Monitoring Extension
21st Dec 202010:08 amRNSHolding(s) in Company
9th Dec 202012:42 pmRNSHolding(s) in Company
24th Nov 20205:37 pmRNSHolding(s) in Company
24th Nov 20207:00 amRNSUpdate on Stereax Manufacturing Implementation
11th Nov 20207:00 amRNSTrading Update & Notice of Results
4th Nov 20207:00 amRNSInvestor Webinar
13th Oct 20204:15 pmRNSHolding(s) in Company
23rd Sep 20207:00 amRNSFramework Agreement with UKBIC
22nd Sep 20201:50 pmRNSResult of AGM
26th Aug 20207:00 amRNSStereax® manufacturing plans update
26th Aug 20207:00 amRNSAnnual Report & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.